Actuate Therapeutics, Inc. (NASDAQ: ACTU) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...
Read moreActuate Therapeutics, Inc. (NASDAQ: ACTU) announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference taking...
Read moreProvivi and Syngenta Biologicals today announced a collaboration to develop and commercialize new pheromone-based biological solutions to effectively and...
Read moreWith the rising demand for real-time data processing, CXL is emerging as a key innovation for modern data centers,...
Read moreActuate Therapeutics, Inc., rang the Nasdaq opening bell in celebration of their IPO. This marks the start of an...
Read moreThe South Jersey company developing new cancer therapies based on the discoveries of a Penn researcher, Linnaeus Therapeutics, has...
Read moreSienza Energy, a Caltech-incubated battery company that is backed by Los Angeles-based philanthropist Patrick Soon-Shiong, demonstrates how its unique and proprietary...
Read moreActuate Therapeutics, Inc. (Nasdaq: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high...
Read moreSivers Semiconductors has entered into a non-binding letter of intent (LOI) to merge its subsidiary Sivers Photonics Ltd of...
Read moreFrom childhood aspirations of being a doctor to a pivotal role in lab operations, Lois Tolvinski’s journey highlights the...
Read more